A compound of Formula I, or a pharmaceutical acceptable salt, tautomer or stereoisomer thereof, wherein n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; L is selected from the group consisting of *-(CHR 3) 1-3 -, *-CHR 3 N(R 2)-, *-CHR 3 O-, *-CHR 3 S-, *-CHR 3 S -, *-CHR 3 N(R 2)CHR 3 -, *-C -, *-C N(R 2)-, *-C N(R 2)CHR 3 -, *-N(R 2)-, *-N(R 2)CHR 3 -, *-N(R 2)C -, *-N(R 2)C N(R 2)-, *-N(R 2)S 2 -, wherein * represents the point of attachment of L to the pyrazolo[1,5-a]pyridine fused ring depicted in Formula I; each R 2 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, R-C 0-4 alkylene, and R-C 0-4 alkylene-C -, wherein R is selected from the group consisting of hydroxyl, C 1-4 alkoxy, amino, C 1-4 alkylamino, C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, and C 5-6 heteroaryl, wherein the C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, and C 5-6 heteroaryl of R are each unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of halo, amino, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, oxo, and C 5-6 heteroaryl; and each R 3 is independently selected from the group consisting of hydrogen and C 1-4 alkyl; Ring A is selected from the group consisting of C 6-10 aryl and C 5-10 heteroaryl; Ring C is selected from the group consisting of C 6-10 aryl, C 5-10 heteroaryl, C 5-7 cycloalkyl, C 5-7 heterocycloalkyl, and fused bicyclyl comprising a C 5-6 heterocycloalky fused to a phenyl; each R 1 is independently selected from the group consisting of halo, cyano, amino, C 1-4 alkyl, C 1-4 alkoxyl, halo-C 1-4 alkyl, -C NR 7 R 8, -NHC R 11, phenyl, and C 5 - 6 heteroaryl; wherein the phenyl and C 5-6 heteroaryl of R 1 are each unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of C 1-4 alkyl, amino, halo, and C 1-4 alkylamino; R 7 and R 8 are each independently selected from hydrogen, C 1-4 alkyl and haloC 1-4 alkyl; R 11 is C 1-6 alkyl, unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of amino, C 3-6 cycloalkyl and C 4-6 heterocycloalkyl; R 17 is selected from the group consisting of cyano, halo, C 1-4 alkyl, halo-C 1-4 alkyl, oxo, C 3-6 cycloalkyl, and -SO 2 -C 1-4 alkyl. n is 0, 1, 2 or 3; p is 0, 1, 2 or 3; L is selected from the group consisting of *-(CHR 3) 1-3 -, *-CHR 3 N(R 2)-, *-CHR 3 O-, *-CHR 3 S-, *-CHR 3 S -, *-CHR 3 N(R 2)CHR 3 -, *-C -, *-C N(R 2)-, *-C N(R 2)CHR 3 -, *-N(R 2)-, *-N(R 2)CHR 3 -, *-N(R 2)C -, *-N(R 2)C N(R 2)-, *-N(R 2)S 2 -, wherein * represents the point of attachment of L to the pyrazolo[1,5-a]pyridine fused ring depicted in Formula I; each R 2 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, R-C 0-4 alkylene, and R-C 0-4 alkylene-C -, wherein R is selected from the group consisting of hydroxyl, C 1-4 alkoxy, amino, C 1-4 alkylamino, C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, and C 5-6 heteroaryl, wherein the C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, and C 5-6 heteroaryl of R are each unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of halo, amino, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, oxo, and C 5-6 heteroaryl; and each R 3 is independently selected from the group consisting of hydrogen and C 1-4 alkyl; * represents the point of attachment of L to the pyrazolo[1,5-a]pyridine fused ring depicted in Formula I; each R 2 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, R-C 0-4 alkylene, and R-C 0-4 alkylene-C -, wherein R is selected from the group consisting of hydroxyl, C 1-4 alkoxy, amino, C 1-4 alkylamino, C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, and C 5-6 heteroaryl, wherein the C 3-6 cycloalkyl, C 4-6 heterocycloalkyl, and C 5-6 heteroaryl of R are each unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of halo, amino, hydroxyl, C 1-4 alkyl, C 1-4 alkoxy, oxo, and C 5-6 heteroaryl; and each R 3 is independently selected from the group consisting of hydrogen and C 1-4 alkyl; Ring A is selected from the group consisting of C 6-10 aryl and C 5-10 heteroaryl; Ring C is selected from the group consisting of C 6-10 aryl, C 5-10 heteroaryl, C 5-7 cycloalkyl, C 5-7 heterocycloalkyl, and fused bicyclyl comprising a C 5-6 heterocycloalky fused to a phenyl; each R 1 is independently selected from the group consisting of halo, cyano, amino, C 1-4 alkyl, C 1-4 alkoxyl, halo-C 1-4 alkyl, -C NR 7 R 8, -NHC R 11, phenyl, and C 5 - 6 heteroaryl; wherein the phenyl and C 5-6 heteroaryl of R 1 are each unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of C 1-4 alkyl, amino, halo, and C 1-4 alkylamino; R 7 and R 8 are each independently selected from hydrogen, C 1-4 alkyl and haloC 1-4 alkyl; R 11 is C 1-6 alkyl, unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of amino, C 3-6 cycloalkyl and C 4-6 heterocycloalkyl; the phenyl and C 5-6 heteroaryl of R 1 are each unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of C 1-4 alkyl, amino, halo, and C 1-4 alkylamino; R 7 and R 8 are each independently selected from hydrogen, C 1-4 alkyl and haloC 1-4 alkyl; R 11 is C 1-6 alkyl, unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of amino, C 3-6 cycloalkyl and C 4-6 heterocycloalkyl; R 17 is selected from the group consisting of cyano, halo, C 1-4 alkyl, halo-C 1-4 alkyl, oxo, C 3-6 cycloalkyl, and -SO 2 -C 1-4 alkyl.